Amir Hefni is Vice President and Global Commercial Head for Cell & Gene, having joined Novartis in May 2020. He leads the global commercialisation of Cell & Gene therapies for Novartis Oncology. Amir joined Novartis from Ipsen, where he was Oncology Brand Global General Manager and led the launch of multiple indications across the globe as well as drove a rich Life Cycle Management program. Previously, he was with Bristol-Myers Squibb (BMS) for 11 years, roles included Executive Director, US Oncology Thoracic Lead, where he led NSCLC, SCLC, and SCCHN. Furthermore, Amir brings a wealth of experience working across different countries including US, UK/Ireland and Sweden. He held various leadership positions at BMS: from Business Unit Head in the UK/Ireland to roles within the Worldwide Commercial group, General Manager in Sweden and International Markets Strategy & Operations. Amir holds a BSc and PhD in Pharmacology from King?s College London, University of London (UK) and a MBA from Warwick Business School, University of Warwick (UK). He also completed the General Management Program at INSEAD in 2017.